[1]
Brenner DM, Sayuk GS. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Advances in therapy. 2020 Jan:37(1):83-96. doi: 10.1007/s12325-019-01116-z. Epub 2019 Nov 9
[PubMed PMID: 31707713]
Level 3 (low-level) evidence
[2]
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. The New England journal of medicine. 2010 Mar 25:362(12):1071-81. doi: 10.1056/NEJMoa0907893. Epub
[PubMed PMID: 20335583]
[3]
Cottreau J, Baker SF, DuPont HL, Garey KW. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert review of anti-infective therapy. 2010 Jul:8(7):747-60. doi: 10.1586/eri.10.58. Epub
[PubMed PMID: 20586560]
[4]
Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Alimentary pharmacology & therapeutics. 2017 Mar:45(5):604-616. doi: 10.1111/apt.13928. Epub 2017 Jan 12
[PubMed PMID: 28078798]
Level 1 (high-level) evidence
[5]
Brandimarte G, Bafutto M, Kruis W, Scarpignato C, Mearin F, Barbara G, Štimac D, Vranić L, Cassieri C, Lecca PG, D'Avino A, Malfertheiner P. Hot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons. Journal of gastrointestinal and liver diseases : JGLD. 2019 Dec 19:28(suppl. 4):23-29. doi: 10.15403/jgld-554. Epub 2019 Dec 19
[PubMed PMID: 31930227]
[6]
Poo S, Sriranganathan D, Segal JP. Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis. European journal of gastroenterology & hepatology. 2022 May 1:34(5):518-528. doi: 10.1097/MEG.0000000000002362. Epub
[PubMed PMID: 35271513]
Level 1 (high-level) evidence
[7]
Goel A, Rahim U, Nguyen LH, Stave C, Nguyen MH. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Alimentary pharmacology & therapeutics. 2017 Dec:46(11-12):1029-1036. doi: 10.1111/apt.14361. Epub 2017 Oct 9
[PubMed PMID: 28994123]
Level 1 (high-level) evidence
[8]
Waqas M, Mohib K, Saleem A, Lnu M, Arjumand S, Khalil HHUR, Nosheen R, Abbas S, Maqsood KM, Abbas K. Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection. Cureus. 2022 Apr:14(4):e24140. doi: 10.7759/cureus.24140. Epub 2022 Apr 14
[PubMed PMID: 35582554]
[9]
Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Current opinion in gastroenterology. 2010 Jan:26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d. Epub
[PubMed PMID: 19881343]
Level 3 (low-level) evidence
[10]
Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005:51 Suppl 1():36-66
[PubMed PMID: 15855748]
[11]
Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World journal of gastroenterology. 2016 Aug 7:22(29):6638-51. doi: 10.3748/wjg.v22.i29.6638. Epub
[PubMed PMID: 27547007]
[15]
Rezaie A, Heimanson Z, McCallum R, Pimentel M. Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. The American journal of gastroenterology. 2019 Dec:114(12):1886-1893. doi: 10.14309/ajg.0000000000000444. Epub
[PubMed PMID: 31688023]
[16]
Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health. Infection and drug resistance. 2020:13():4713-4738. doi: 10.2147/IDR.S290835. Epub 2020 Dec 29
[PubMed PMID: 33402841]
[17]
Jones LK, Ladd IG, Gregor C, Evans MA, Graham J, Gionfriddo MR. Understanding the medication prior-authorization process: A case study of patients and clinical staff from a large rural integrated health delivery system. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2019 Mar 19:76(7):453-459. doi: 10.1093/ajhp/zxy083. Epub
[PubMed PMID: 31361821]
Level 3 (low-level) evidence